We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Plavix Ruling Raises Learned Intermediary Questions

Law360, New York (December 4, 2017, 12:31 PM EST) -- A federal judge in New Jersey recently granted summary judgment to Plavix drug makers Bristol Myers-Squibb Company (BMS), Sanofi-Aventis U.S. LLC, Sanofi-Aventis U.S. Inc. and Sanofi-Synthelabo Inc. in a lawsuit alleging that the plaintiff’s gastrointestinal bleeding was caused by the defendants’ prescription drug Plavix.

The plaintiff alleged that she suffered injuries as a result of the defendants’ design, development, manufacture, promoting, marketing, distributing, labeling and sale of Plavix, an anti-clotting medication.

Plavix was initially approved by the FDA for individuals with recent heart attack, stroke (including...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.